Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Die Highlights vom Kongress des American College of Cardiology 2024

Im April diskutierten die Herz-Kreislauf-Spezialisten aus der ganzen Welt auf dem  Kongress des American College of Cardiology (ACC) u.a. neue Therapieansätze bei akutem Myokardinfarkt, koronarer Herzerkrankung, kardiogenem Schock oder Aortenklappenstenose. In unserem Kongress-Dossier haben wir für Sie Berichte über die „Late-Breaking Trials“ und andere wichtige Studien zusammengestellt. 
Erweiterte Suche
Anmelden
nach oben
Current Diabetes Reports
Erschienen in: Current Diabetes Reports 8/2014

01.08.2014 | Transplantation (A Pileggi, Section Editor)

Autologous Islet Transplantation in Patients Requiring Pancreatectomy for Neoplasm

verfasst von: Gianpaolo Balzano, Lorenzo Piemonti

Erschienen in: Current Diabetes Reports | Ausgabe 8/2014

Einloggen, um Zugang zu erhalten

Abstract

Autologous islet cell transplantation is a procedure performed to prevent or reduce the severity of diabetes after pancreatic resection. Autologous islet cell transplantation is being used almost exclusively in patients undergoing pancreatectomy because of painful, chronic pancreatitis, or multiple recurrent episodes of pancreatitis that is not controlled by standard medical and surgical treatments. Here, we discuss the possibility of extending the clinical indications for this treatment on the basis of our experience in patients undergoing pancreatic surgery for both nonmalignant and malignant diseases, including patients undergoing completion pancreatectomy because of anastomosis leakage after pancreaticoduodenectomy and those with pancreatic anastomosis deemed at high risk for failure.
Literatur
1.•
Maeda H, Hanazaki K. Pancreatogenic diabetes after pancreatic resection. Pancreatology. 2011;11:268–76. This is a state-of-the-art review of pancreatogenic diabetes.PubMedCrossRef
2.
Cui Y, Andersen DK. Pancreatogenic diabetes: special considerations for management. Pancreatology. 2011;11:279–94.PubMedCrossRef
3.••
Parsaik AK, Murad MH, Sathananthan A, et al. Metabolic and target organ outcomes after total pancreatectomy: Mayo Clinic experience and meta-analysis of the literature. Clin Endocrinol. 2010;73:723–31. This systematic review and meta-analysis focused on the clinical outcomes of total pancreatectomy in a large tertiary center, demonstrating that hypoglycemic episodes continue to be a major problem of pancreatogenic diabetes.CrossRef
4.
5.
Jethwa P, Sodergren M, Lala A, et al. Diabetic control after total pancreatectomy. Dig Liver Dis. 2006;38:415–9.PubMedCrossRef
6.
Stauffer JA, Nguyen JH, Heckman MG, et al. Patient outcomes after total pancreatectomy: a single centre contemporary experience. HPB (Oxford). 2009;11:483–92.CrossRef
7.
Muller MW, Friess H, Kleeff J, et al. Is there still a role for total pancreatectomy? Ann Surg. 2007;246:966–74. discussion 974–5.PubMedCrossRef
8.
Lahat G, Ben Haim M, Nachmany I, et al. Pancreatic incidentalomas: high rate of potentially malignant tumors. J Am Coll Surg. 2009;209:313–9.PubMedCrossRef
9.
Lemmens VE, Bosscha K, van der Schelling G, et al. Improving outcome for patients with pancreatic cancer through centralization. Br J Surg. 2011;98:1455–62.PubMedCrossRef
10.
Balzano G, Zerbi A, Capretti G, et al. Effect of hospital volume on outcome of pancreaticoduodenectomy in Italy. Br J Surg. 2008;95:357–62.PubMedCrossRef
11.
Priestley JT, Comfort MW, Sprague RG. Total pancreatectomy for hyperinsulinism due to islet-cell adenoma: follow-up report 5 1/2 years after operation, including metabolic studies. Ann Surg. 1949;130:211–7.PubMedCentralPubMedCrossRef
12.
Slezak LA, Andersen DK. Pancreatic resection: effects on glucose metabolism. World J Surg. 2001;25:452–60.PubMedCrossRef
13.
Alberti K. Diabetes secondary to pancreatopathy: an example of brittle diabetes. In: Diabetes Secondary to Pancreatopathy. International Congress Series 762. Tiengo A, DelPrato S, Vranic M, editors. Amsterdam: Excerpta Medica; 1988. p. 7–20.
14.
Billings BJ, Christein JD, Harmsen WS, et al. Quality-of-life after total pancreatectomy: is it really that bad on long-term follow-up? J Gastrointest Surg. 2005;9:1059–66. discussion 1066–7.PubMedCrossRef
15.
Kahl S, Malfertheiner P. Exocrine and endocrine pancreatic insufficiency after pancreatic surgery. Best Pract Res Clin Gastroenterol. 2004;18:947–55.PubMedCrossRef
16.
Hutchins RR, Hart RS, Pacifico M, et al. Long-term results of distal pancreatectomy for chronic pancreatitis in 90 patients. Ann Surg. 2002;236:612–8.PubMedCentralPubMedCrossRef
17.
Hutchins RR, Kojodjojo P, Ho R, et al. Short and long-term outcome of pancreatic surgery in a district general hospital. J R Coll Surg Edinb. 2002;47:548–51.PubMed
18.
Reddy S, Wolfgang CL, Cameron JL, et al. Total pancreatectomy for pancreatic adenocarcinoma: evaluation of morbidity and long-term survival. Ann Surg. 2009;250:282–7.PubMedCrossRef
19.
Sakata N, Egawa S, Motoi F, et al. Institutional indications for islet transplantation after total pancreatectomy. J Hepatobiliary Pancreat Surg. 2008;15:488–92.PubMedCrossRef
20.
Gaia E, Salacone P. Medical complications of pancreatic resections. JOP. 2007;8:114–7.PubMed
21.
Andersen DK, Andren-Sandberg A, Duell EJ, et al. Pancreatitis-diabetes-pancreatic cancer: summary of an NIDDK-NCI workshop. Pancreas. 2013;42:1227–37.PubMedCrossRef
22.
Roberts KJ, Blanco G, Webber J, et al. How severe is diabetes after total pancreatectomy? A case-matched analysis. HPB (Oxford). 2013
23.
Nosadini R, del Prato S, Tiengo A, et al. Insulin sensitivity, binding, and kinetics in pancreatogenic and type I diabetes. Diabetes. 1982;31:346–55.PubMedCrossRef
24.
Gall FP, Muhe E, Gebhardt C. Results of partial and total pancreaticoduodenectomy in 117 patients with chronic pancreatitis. World J Surg. 1981;5:269–75.PubMedCrossRef
25.
Muggeo M, Moghetti P, Faronato PP, et al. Insulin receptors on circulating blood cells from patients with pancreatogenic diabetes: a comparison with type I diabetes and normal subjects. J Endocrinol Invest. 1987;10:311–9.PubMedCrossRef
26.
Seymour NE, Volpert AR, Lee EL, et al. Alterations in hepatocyte insulin binding in chronic pancreatitis: effects of pancreatic polypeptide. Am J Surg. 1995;169:105–9. discussion 110.PubMedCrossRef
27.
Andersen DK, Ruiz CL, Burant CF. Insulin regulation of hepatic glucose transporter protein is impaired in chronic pancreatitis. Ann Surg. 1994;219:679–86. discussion 686–7.PubMedCentralPubMedCrossRef
28.
Seymour NE, Spector SA, Andersen DK, et al. Overexpression of hepatic pancreatic polypeptide receptors in chronic pancreatitis. J Surg Res. 1998;76:47–52.PubMedCrossRef
29.
Inoue K, Tobe T, Suzuki T, et al. Plasma cholecystokinin and pancreatic polypeptide response after radical pancreatoduodenectomy with Billroth I and Billroth II type of reconstruction. Ann Surg. 1987;206:148–54.PubMedCentralPubMedCrossRef
30.
Sive A, Vinik AI, Van Tonder S, Lund A. Impaired pancreatic polypeptide secretion in chronic pancreatitis. J Clin Endocrinol Metab. 1978;47:556–9.PubMedCrossRef
31.
Adrian TE, McKiernan J, Johnstone DI, et al. Hormonal abnormalities of the pancreas and gut in cystic fibrosis. Gastroenterology. 1980;79:460–5.PubMed
32.
Bajorunas DR, Fortner JG, Jaspan J, Sherwin RS. Total pancreatectomy increases the metabolic response to glucagon in humans. J Clin Endocrinol Metab. 1986;63:439–46.PubMedCrossRef
33.
Schrader H, Menge BA, Breuer TG, et al. Impaired glucose-induced glucagon suppression after partial pancreatectomy. J Clin Endocrinol Metab. 2009;94:2857–63.PubMedCrossRef
34.
Donowitz M, Hendler R, Spiro HM, et al. Glucagon secretion in acute and chronic pancreatitis. Ann Intern Med. 1975;83:778–81.PubMedCrossRef
35.
36.
Knop FK, Vilsboll T, Larsen S, et al. Increased postprandial responses of GLP-1 and GIP in patients with chronic pancreatitis and steatorrhea following pancreatic enzyme substitution. Am J Physiol Endocrinol Metab. 2007;292:E324–30.PubMedCrossRef
37.
Ewald N, Bretzel RG, Fantus IG, et al. Pancreatin therapy in patients with insulin-treated diabetes mellitus and exocrine pancreatic insufficiency according to low fecal elastase 1 concentrations. Results of a prospective multi-center trial. Diabetes Metab Res Rev. 2007;23:386–91.PubMedCrossRef
38.
Kendall DM, Sutherland DE, Najarian JS, et al. Effects of hemipancreatectomy on insulin secretion and glucose tolerance in healthy humans. N Engl J Med. 1990;322:898–903.PubMedCrossRef
39.
Kumar AF, Gruessner RW, Seaquist ER. Risk of glucose intolerance and diabetes in hemipancreatectomized donors selected for normal preoperative glucose metabolism. Diabetes Care. 2008;31:1639–43.PubMedCentralPubMedCrossRef
40.
Malka D, Hammel P, Sauvanet A, et al. Risk factors for diabetes mellitus in chronic pancreatitis. Gastroenterology. 2000;119:1324–32.PubMedCrossRef
41.
Andersen DK, Frey CF. The evolution of the surgical treatment of chronic pancreatitis. Ann Surg. 2010;251:18–32.PubMedCrossRef
42.
Bellin MD, Balamurugan AN, Pruett TL, Sutherland DE. No islets left behind: islet autotransplantation for surgery-induced diabetes. Curr Diab Rep. 2012;12:580–6.PubMedCentralPubMedCrossRef
43.
Bramis K, Gordon-Weeks AN, Friend PJ, et al. Systematic review of total pancreatectomy and islet autotransplantation for chronic pancreatitis. Br J Surg. 2012;99:761–6.PubMedCrossRef
44.
Dong M, Parsaik AK, Erwin PJ, et al. Systematic review and meta-analysis: islet autotransplantation after pancreatectomy for minimizing diabetes. Clin Endocrinol. 2011;75:771–9.CrossRef
45.
Najarian JS, Sutherland DE, Matas AJ, Goetz FC. Human islet autotransplantation following pancreatectomy. Transplant Proc. 1979;11:336–40.PubMed
46.
Piemonti L, Pileggi A. 25 Years of the Ricordi Automated Method for islet isolation. CellR4. 2013;1:e128.
47.••
Sutherland DE, Radosevich DM, Bellin MD, et al. Total pancreatectomy and islet autotransplantation for chronic pancreatitis. J Am Coll Surg. 2012;214:409–24. This is the largest published cohort of IAT after pancreatectomy for chronic pancreatitis.PubMedCentralPubMedCrossRef
48.
Bellin MD, Beilman GJ, Dunn TB, et al. Islet autotransplantation to preserve beta cell mass in selected patients with chronic pancreatitis and diabetes mellitus undergoing total pancreatectomy. Pancreas. 2013;42:317–21.PubMedCentralPubMedCrossRef
49.
Bellin MD, Freeman ML, Schwarzenberg SJ, et al. Quality of life improves for pediatric patients after total pancreatectomy and islet autotransplant for chronic pancreatitis. Clin Gastroenterol Hepatol. 2011;9:793–9.PubMedCentralPubMedCrossRef
50.
Bellin MD, Carlson AM, Kobayashi T, et al. Outcome after pancreatectomy and islet autotransplantation in a pediatric population. J Pediatr Gastroenterol Nutr. 2008;47:37–44.PubMedCrossRef
51.
Wilson GC, Sutton JM, Salehi M, et al. Surgical outcomes after total pancreatectomy and islet cell autotransplantation in pediatric patients. Surgery. 2013;154:777–83. discussion 783–4.PubMedCrossRef
52.
Sutton JM, Schmulewitz N, Sussman JJ, et al. Total pancreatectomy and islet cell autotransplantation as a means of treating patients with genetically linked pancreatitis. Surgery. 2010;148:676–85. discussion 685–6.PubMedCrossRef
53.
Webb MA, Illouz SC, Pollard CA, et al. Islet auto transplantation following total pancreatectomy: a long-term assessment of graft function. Pancreas. 2008;37:282–7.PubMedCrossRef
54.
Clayton HA, Davies JE, Pollard CA, et al. Pancreatectomy with islet autotransplantation for the treatment of severe chronic pancreatitis: the first 40 patients at the Leicester General Hospital. Transplantation. 2003;76:92–8.PubMedCrossRef
55.
White SA, Davies JE, Pollard C, et al. Pancreas resection and islet autotransplantation for end-stage chronic pancreatitis. Ann Surg. 2001;233:423–31.PubMedCentralPubMedCrossRef
56.
Garcea G, Weaver J, Phillips J, et al. Total pancreatectomy with and without islet cell transplantation for chronic pancreatitis: a series of 85 consecutive patients. Pancreas. 2009;38:1–7.PubMedCrossRef
57.
Ahmad SA, Lowy AM, Wray CJ, et al. Factors associated with insulin and narcotic independence after islet autotransplantation in patients with severe chronic pancreatitis. J Am Coll Surg. 2005;201:680–7.PubMedCrossRef
58.
Morgan KA, Nishimura M, Uflacker R, Adams DB. Percutaneous transhepatic islet cell autotransplantation after pancreatectomy for chronic pancreatitis: a novel approach. HPB (Oxford). 2011;13:511–6.CrossRef
59.
Sutherland DE, Gruessner AC, Carlson AM, et al. Islet autotransplant outcomes after total pancreatectomy: a contrast to islet allograft outcomes. Transplantation. 2008;86:1799–802.PubMedCrossRef
60.
Dudeja V, Beilman GJ, Vickers SM. Total pancreatectomy with islet autotransplantation in patients with malignancy: are we there yet? Ann Surg. 2013;258:219–20.PubMedCrossRef
61.••
Balzano G, Maffi P, Nano R, et al. Extending indications for islet autotransplantation in pancreatic surgery. Ann Surg. 2013;258:210–8. This is the largest published cohort of IAT after pancreatectomy for diseases other than chronic pancreatitis.PubMedCrossRef
62.•
Ris F, Niclauss N, Morel P, et al. Islet autotransplantation after extended pancreatectomy for focal benign disease of the pancreas. Transplantation. 2011;91:895–901. This article reports on a cohort of IAT after partial pancreatectomy for benign neoplasm with longer follow-up.PubMedCrossRef
63.•
Jin SM, Oh SH, Kim SK, et al. Diabetes-free survival in patients who underwent islet autotransplantation after 50 % to 60 % distal partial pancreatectomy for benign pancreatic tumors. Transplantation. 2013;95:1396–403. This is the largest published cohort of IAT after partial pancreatectomy for benign neoplasm.PubMedCrossRef
64.
Launois B, Franci J, Bardaxoglou E, et al. Total pancreatectomy for ductal adenocarcinoma of the pancreas with special reference to resection of the portal vein and multicentric cancer. World J Surg. 1993;17:122–6. discussion 126–7.PubMedCrossRef
65.
66.
Motojima K, Urano T, Nagata Y, et al. Detection of point mutations in the Kirsten-ras oncogene provides evidence for the multicentricity of pancreatic carcinoma. Ann Surg. 1993;217:138–43.PubMedCentralPubMedCrossRef
67.
Balamurugan AN, Loganathan G, Bellin MD, et al. A new enzyme mixture to increase the yield and transplant rate of autologous and allogeneic human islet products. Transplantation. 2012;93:693–702.PubMedCentralPubMedCrossRef
68.
Karpoff HM, Klimstra DS, Brennan MF, Conlon KC. Results of total pancreatectomy for adenocarcinoma of the pancreas. Arch Surg. 2001;136:44–7. discussion 48.PubMedCrossRef
69.
Schnelldorfer T, Lombardo KR, Farnell M, Sarr M. Total Pancreatectomy for Treatment of Pancreatic Adenocarcinoma. In: Lowy A, Leach S, Philip P, editors. Pancreatic Cancer. US: Springer; 2008. p. p. 329–39.CrossRef
70.
Kloppel G, Lohse T, Bosslet K, Ruckert K. Ductal adenocarcinoma of the head of the pancreas: incidence of tumor involvement beyond the Whipple resection line. Histological and immunocytochemical analysis of 37 total pancreatectomy specimens. Pancreas. 1987;2:170–5.PubMedCrossRef
71.
Kobayashi T, Sato Y, Hirukawa H, et al. Total pancreatectomy combined with partial pancreas autotransplantation for recurrent pancreatic cancer: a case report. Transplant Proc. 2012;44:1176–9.PubMedCrossRef
72.
Alsaif F, Molinari M, Al-Masloom A, et al. Pancreatic islet autotransplantation with completion pancreatectomy in the management of uncontrolled pancreatic fistula after whipple resection for ampullary adenocarcinoma. Pancreas. 2006;32:430–1.PubMedCrossRef
73.
Forster S, Liu X, Adam U, et al. Islet autotransplantation combined with pancreatectomy for treatment of pancreatic adenocarcinoma: a case report. Transplant Proc. 2004;36:1125–6.PubMedCrossRef
74.
Iyegha UP, Asghar JA, Beilman GJ. Total pancreatectomy and islet auto-transplantation as treatment for ampullary adenocarcinoma in the setting of pancreatic ductal disruption secondary to acute necrotizing pancreatitis. A case report. JOP. 2012;13:239–42.PubMed
75.
Lee BW, Jee JH, Heo JS, et al. The favorable outcome of human islet transplantation in Korea: experiences of 10 autologous transplantations. Transplantation. 2005;79:1568–74.PubMedCrossRef
76.
Callery MP, Pratt WB, Vollmer Jr CM. Prevention and management of pancreatic fistula. J Gastrointest Surg. 2009;13:163–73.PubMedCrossRef
77.
Kuroki T, Tajima Y, Kanematsu T. Surgical management for the prevention of pancreatic fistula following distal pancreatectomy. J Hepatobiliary Pancreat Surg. 2005;12:283–5.PubMedCrossRef
78.
Niedergethmann M, Farag Soliman M, Post S. Postoperative complications of pancreatic cancer surgery. Minerva Chir. 2004;59:175–83.PubMed
79.
Bassi C, Dervenis C, Butturini G, et al. Postoperative pancreatic fistula: an international study group (ISGPF) definition. Surgery. 2005;138:8–13.PubMedCrossRef
80.
Bassi C, Butturini G, Molinari E, et al. Pancreatic fistula rate after pancreatic resection. The importance of definitions. Dig Surg. 2004;21:54–9.PubMedCrossRef
81.
Yeo CJ, Cameron JL, Maher MM, et al. A prospective randomized trial of pancreaticogastrostomy vs pancreaticojejunostomy after pancreaticoduodenectomy. Ann Surg. 1995;222:580–8. discussion 588–92.PubMedCentralPubMedCrossRef
82.
Strasberg SM, Linehan DC, Clavien PA, Barkun JS. Proposal for definition and severity grading of pancreatic anastomosis failure and pancreatic occlusion failure. Surgery. 2007;141:420–6.PubMedCrossRef
83.
Richter A, Niedergethmann M, Sturm JW, et al. Long-term results of partial pancreaticoduodenectomy for ductal adenocarcinoma of the pancreatic head: 25-year experience. World J Surg. 2003;27:324–9.PubMedCrossRef
84.
Batignani G, Fratini G, Zuckermann M, et al. Comparison of Wirsung-jejunal duct-to-mucosa and dunking technique for pancreatojejunostomy after pancreatoduodenectomy. Hepatobiliary Pancreat Dis Int. 2005;4:450–5.PubMed
85.
Yeo CJ. The Johns Hopkins experience with pancreaticoduodenectomy with or without extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma. J Gastrointest Surg. 2000;4:231–2.PubMedCrossRef
86.
Matsumoto Y, Fujii H, Miura K, et al. Successful pancreatojejunal anastomosis for pancreatoduodenectomy. Surg Gynecol Obstet. 1992;175:555–62.PubMed
87.
Kojima Y, Katayama K, Note M, et al. Pancreaticojejunostomy and pancreatic leakage after pancreaticoduodenectomy. Int Surg. 1992;77:80–3.PubMed
88.
Kollmar O, Moussavian MR, Bolli M, et al. Pancreatojejunal leakage after pancreas head resection: anatomic and surgeon-related factors. J Gastrointest Surg. 2007;11:1699–703.PubMedCrossRef
89.
Pratt WB, Callery MP, Vollmer Jr CM. Risk prediction for development of pancreatic fistula using the ISGPF classification scheme. World J Surg. 2008;32:419–28.PubMedCrossRef
90.
Balzano G, Pecorelli N, Piemonti L, et al. Relaparotomy for a pancreatic fistula after a pancreaticoduodenectomy: a comparison of different surgical strategies. HPB (Oxford). 2014;16:40–5.CrossRef
91.
Christoffersson G, Henriksnas J, Johansson L, et al. Clinical and experimental pancreatic islet transplantation to striated muscle: establishment of a vascular system similar to that in native islets. Diabetes. 2010;59:2569–78.PubMedCentralPubMedCrossRef
92.
Berney T, Mathe Z, Bucher P, et al. Islet autotransplantation for the prevention of surgical diabetes after extended pancreatectomy for the resection of benign tumors of the pancreas. Transplant Proc. 2004;36:1123–4.PubMedCrossRef
93.
Oberholzer J, Mathe Z, Bucher P, et al. Islet autotransplantation after left pancreatectomy for non-enucleable insulinoma. Am J Transplant. 2003;3:1302–7.PubMedCrossRef
94.
Garraway NR, Dean S, Buczkowski A, et al. Islet autotransplantation after distal pancreatectomy for pancreatic trauma. J Trauma. 2009;67:E187–9.PubMedCrossRef
95.
Dardenne S, Sterkers A, Leroy C, et al. Laparoscopic spleen-preserving distal pancreatectomy followed by intramuscular autologous islet transplantation for traumatic pancreatic transection in a young adult. JOP. 2012;13:285–8.PubMed
96.
Sakata N, Goto M, Motoi F, et al. Clinical experiences in the treatment of pancreatic arteriovenous malformation by total pancreatectomy with islet autotransplantation. Transplantation. 2013;96:e38–40.PubMedCrossRef
97.
Jung HS, Choi SH, Kim SJ, et al. Delayed improvement of insulin secretion after autologous islet transplantation in partially pancreatectomized patients. Metabolism. 2009;58:1629–35.PubMedCrossRef
98.
Gala-Lopez BL, Semlacher E, Manouchehri N, et al. Autologous islet transplantation after total pancreatectomy for renal cell carcinoma metastases. Am J Transplant. 2013;13:2487–91.PubMedCrossRef
99.
Khan A, Jindal RM, Shriver C, et al. Remote processing of pancreas can restore normal glucose homeostasis in autologous islet transplantation after traumatic whipple pancreatectomy: technical considerations. Cell Transplant. 2012;21:1261–7.PubMedCrossRef
100.
Jindal RM, Ricordi C, Shriver CD. Autologous pancreatic islet transplantation for severe trauma. N Engl J Med. 2010;362:1550.PubMedCrossRef
101.
Liu X, Forster S, Adam U, et al. Islet autotransplantation combined with total pancreatectomy for treatment of pancreatic adenocarcinoma. Transplant Proc. 2001;33:662–3.PubMedCrossRef
Metadaten
Titel
Autologous Islet Transplantation in Patients Requiring Pancreatectomy for Neoplasm
verfasst von
Gianpaolo Balzano
Lorenzo Piemonti
Publikationsdatum
01.08.2014
Verlag
Springer US
Erschienen in
Current Diabetes Reports / Ausgabe 8/2014
Print ISSN: 1534-4827
Elektronische ISSN: 1539-0829
DOI
https://doi.org/10.1007/s11892-014-0512-2

Weitere Artikel der Ausgabe 8/2014

Current Diabetes Reports 8/2014 Zur Ausgabe

Psychosocial Aspects (KK Hood, Section Editor)

Goal Setting: An Integral Component of Effective Diabetes Care

Microvascular Complications—Retinopathy (JK Sun, Section Editor)

Genetics of Diabetic Retinopathy

Microvascular Complications—Nephropathy (B Roshan, Section Editor)

Resistant Hypertension in Diabetes Mellitus

Obesity (J McCaffery, Section Editor)

Obesity and Type 2 Diabetes in Children: Epidemiology and Treatment

Microvascular Complications—Retinopathy (JK Sun, Section Editor)

Anti-VEGF Therapy for Diabetic Macular Edema

Diabetes and Other Diseases-Emerging Associations (JJ Nolan, Section Editor)

Cystic Fibrosis Related Diabetes

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

CAR-M-Zellen: Warten auf das große Fressen

22.05.2024 Onkologische Immuntherapie Nachrichten

Auch myeloide Immunzellen lassen sich mit chimären Antigenrezeptoren gegen Tumoren ausstatten. Solche CAR-Fresszell-Therapien werden jetzt für solide Tumoren entwickelt. Künftig soll dieser Prozess nicht mehr ex vivo, sondern per mRNA im Körper der Betroffenen erfolgen.

Frühzeitige HbA1c-Kontrolle macht sich lebenslang bemerkbar

22.05.2024 Typ-2-Diabetes Nachrichten

Menschen mit Typ-2-Diabetes von Anfang an intensiv BZ-senkend zu behandeln, wirkt sich positiv auf Komplikationen und Mortalität aus – und das offenbar lebenslang, wie eine weitere Nachfolgeuntersuchung der UKPD-Studie nahelegt.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise